Nonlinear pharmacodynamics of levodopa through Parkinson's disease progression.

作者: Florence Véronneau-Veilleux , Mauro Ursino , Philippe Robaey , Daniel Lévesque , Fahima Nekka

DOI: 10.1063/5.0014800

关键词:

摘要: The effect of levodopa in alleviating the symptoms Parkinson’s disease is altered a highly nonlinear manner as progresses. This can be attributed to different compensation mechanisms taking place basal ganglia where dopaminergic neurons are progressively lost. alteration complicates optimization drug regimen. present work aims at investigating dynamics and its therapy through mechanistic mathematical modeling. Using holistic approach, pharmacokinetic model was combined dopamine neurocomputational ganglia. influence neuronal death on these also integrated. this model, we were able investigate relationships between plasma concentration, brain response motor task. Variations concentrations for doses studied. Finally, investigated narrowing therapeutic index with progression result nonlinearities. In conclusion, various consequences treatment studied by developing an integrative model. paves way toward individualization dosing sensor based information, parameters could fitted individual data propose optimal regimens.

参考文章(40)
J. K. Dreyer, Three Mechanisms by which Striatal Denervation Causes Breakdown of Dopamine Signaling The Journal of Neuroscience. ,vol. 34, pp. 12444- 12456 ,(2014) , 10.1523/JNEUROSCI.1458-14.2014
Horst Baas, Frank Zehrden, Roland Selzer, Ralf Kohnen, Joern Loetsch, Sebastian Harder, Pharmacokinetic-Pharmacodynamic Relationship of Levodopa with and without Tolcapone in Patients with Parkinson’s Disease Clinical Pharmacokinectics. ,vol. 40, pp. 383- 393 ,(2001) , 10.2165/00003088-200140050-00005
Sushil Sharma, Carolyn Seungyoun Moon, Azza Khogali, Ali Haidous, Anthony Chabenne, Comfort Ojo, Miriana Jelebinkov, Yousef Kurdi, Manuchair Ebadi, Biomarkers in Parkinson's disease (recent update). Neurochemistry International. ,vol. 63, pp. 201- 229 ,(2013) , 10.1016/J.NEUINT.2013.06.005
Phylinda L. S. Chan, John G. Nutt, Nicholas H. G. Holford, Pharmacokinetic and Pharmacodynamic Changes During the First Four Years of Levodopa Treatment in Parkinson’s Disease Journal of Pharmacokinetics and Pharmacodynamics. ,vol. 32, pp. 459- 484 ,(2005) , 10.1007/S10928-005-0055-X
Yves Agid, Parkinson's disease: pathophysiology. The Lancet. ,vol. 337, pp. 1321- 1324 ,(1991) , 10.1016/0140-6736(91)92989-F
M. Contin, R. Riva, P. Martinelli, P. Cortelli, F. Albani, A. Baruzzi, A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease Neurology. ,vol. 51, pp. 1075- 1080 ,(1998) , 10.1212/WNL.51.4.1075
Mohammad Haeri, Yashar Sarbaz, Shahriar Gharibzadeh, Modeling the Parkinson's tremor and its treatments Journal of Theoretical Biology. ,vol. 236, pp. 311- 322 ,(2005) , 10.1016/J.JTBI.2005.03.014
Werner Poewe, Angelo Antonini, Jan CM Zijlmans, Pierre R Burkhard, François Vingerhoets, Levodopa in the treatment of Parkinson's disease: an old drug still going strong. Clinical Interventions in Aging. ,vol. 5, pp. 229- 238 ,(2010) , 10.2147/CIA.S6456
C Warren Olanow, Anthony HV Schapira, Olivier Rascol, None, Continuous dopamine-receptor stimulation in early Parkinson's disease Trends in Neurosciences. ,vol. 23, pp. S117- S126 ,(2000) , 10.1016/S1471-1931(00)00030-6